Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2026)

Xeris Biopharma Holdings has reported EBT Margin for 7 years, with the latest figure at 2.69% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 1802.0% year-over-year to 2.69%; the trailing twelve-month figure through Mar 2026 stood at 3.81% (up 2523.0% YoY), and the FY2025 full-year result was 0.19%, up 2831.0% from the prior year.
• EBT Margin for Q1 2026 stood at 2.69%, down from 12.91% in the prior quarter.
• The five-year high for EBT Margin was 12.91% in Q4 2025, with the low at 154.59% in Q1 2022.
• Historically, EBT Margin has averaged 38.6% across 5 years, with a median of 30.7% in 2023.
• Annual changes were most pronounced in 2022 — EBT Margin surged 20414 bps — and 2024, when it tumbled 920 bps.
• Xeris Biopharma Holdings' EBT Margin stood at 40.03% in 2022, then grew by 23 bps to 30.7% in 2023, then surged by 72 bps to 8.51% in 2024, then jumped by 252 bps to 12.91% in 2025, then slumped by 79 bps to 2.69% in 2026.
• The last three EBT Margin figures came in at 2.69% (Q1 2026), 12.91% (Q4 2025), and 0.83% (Q3 2025), per Business Quant data.